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Abstract: Trazodone is an antidepressant which behaves as a selective 5-HT2 antagonist 
and 5-HT reuptake inhibitor. The lack of information on its effects in vivo prompted us to 
evaluate α2-adrenoceptors by means of the specific binding of [3H]-rauwolscine, and the 5-HT 
transporter (SERT) by means of the binding of [3H]-paroxetine ([3H]-Par), in platelets of 
depressed patients, before and after one month of treatment with trazodone (75–300 mg/day).
Twenty-five outpatients of both sexes with a diagnosis of major depression, as assessed by the 
Structured Clinical Interview for DSM IV , were included in the study. Depressive symptoms were 
evaluated by means of the Hamilton Rating Scale for Depression: the total score (mean ± SD) 
was 20 ± 6 at baseline (t0) and 7 ± 4 after one month of treatment (t1). Platelet membranes, [3H]-
rauwolscine and [3H]-Par bindings were carried out according to standardized protocols. The 
results showed that the Bmax values of [3H]-Par were statistically lower at t1 than at t0 (733 ± 30 
vs 1471 ± 99, P , 0.001), while the Kd and the [3H]-rauwolscine binding parameters remained 
unchanged. The findings of this study suggest that in vivo trazodone modifies the number of 
the SERT proteins and that, perhaps, most of its antidepressant properties are related to this 
activity.
Keywords: trazodone, depression, serotonin, platelets, α2-adrenoreceptors, [3H]-rauwolscine, 
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Introduction
Trazodone is a compound deriving from phenylpiperazines widely-used in the 
United States and Europe since the beginning of the 1980s as an antidepressant 
characterized by lower anticholinergic properties and lower cardiac conduction effects 
than tricyclics.1–4 Trazodone behaves like an antagonist of serotonin (5-HT) recep-
tors of type 2 (5-HT2) and of α-adrenoreceptors, as well as like an inhibitor of 5-HT 
reuptake.5,6 Together with nefazodone, it belongs to the class of the so-called 5-HT2 
antagonists and 5-HT inhibitors (SARIs).
The inhibition of the reuptake increases the intrasynaptic 5-HT levels leading to 
indiscriminate stimulation of all 5-HT receptors. If the first activity is related to the 
antidepressant effect, the second is at the basis of some side-effects typically displayed 
by selective serotonin reuptake inhibitors (SSRIs). Indeed, raphe 5-HT1 stimulation 
is responsible for the antidepressant efficacy, while proencefalic 5-HT2 stimulation 
induces agitation, anxiety and sexual dysfunctions. Therefore, compounds such as 
trazodone that inhibit 5-HT reuptake, but antagonize only specific 5-HT receptors, 
seem to reduce significantly some side-effects deriving from an excessive increase of 
5-HT concentrations and receptor stimulation.7Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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The antidepressant properties of trazodone have been 
demonstrated in different clinical placebo-controlled studies 
and compared also with those of other antidepressants.4,8,9 
From such trials, it emerged that it is an effective com-
pound with a good tolerability profile similar to that of 
placebo: in fact, the incidence of side-effects ranges between 
15 and 30% in both trazodone and placebo users. The 
anticholinergic side effects, particularly dry mouth, blurred 
vision, constipation, and urinary retention are rare, as they 
are those due to α-adrenoreceptor blockade, such as hypoten-
sion and sedation. Interestingly, trazodone treatment has been 
seldom associated with priapism,10,11 a characteristic that can 
be used to revert the sexual dysfunctions provoked by other 
psychotropic drugs.12
Although the pharmacodynamic aspects of trazodone 
are well known, no information is available on its effects on 
peripheral noradrenergic and serotonergic markers in vivo. For 
three decades, platelets have been widely used in biological 
psychiatry as a reliable, peripheral model of serotonergic 
neurons.13 In particular, blood platelets and neurons share a 
similar 5-HT reuptake system, the 5-HT transporter (SERT)14,15 
and other receptors, such as α2-adrenoceptors. Therefore, our 
study aimed to evaluate α2-adrenoceptors, by means of the 
specific binding of [3H]-rauwolscine, a selective antagonist of 
their levels, and the 5-HT transporter (SERT) by means of the 
binding of [3H]-paroxetine ([3H]-Par), in platelets of depressed 
patients, before and after one month’s treatment with trazodone. 
In addition, we explored the possible correlation between 
kinetic parameters of [3H]-rauwolscine and [3H]-Par bindings 
and demographic or clinical characteristics of the patients.
Materials and methods
Subjects
Twenty-five outpatients (12 women, 13 men, between 23 
and 50 years of age, mean ± SD: 32.3 ± 9.5), recruited at the 
Dipartimento di Psichiatria, Neurobiologia, Farmacologia e 
Biotecnologie, University of Pisa, Italy, with a diagnosis of 
major depression, as assessed by the Structured Clinical Inter-
view for DSM IV ,16 were included in the study. Fifteen patients 
were suffering from recurrent unipolar depression and 10 
from bipolar disorder (BD): in particular, three suffered from 
BD of type 1 and seven from BD of type 2. The [3H]-Par 
binding assay was carried out in all patients, while the [3H]-
rauwolscine binding was carried out in only 21 (10 women, 11 
men, age between 23 and 48 years; mean ± SD: 35.8 ± 10.5). 
None had taken tricyclic antidepressants in the last year, 
three had taken SSRIs (citalopram, sertraline, escitalopram) 
30 days before the enrollment and two were currently taking 
mood stabilizers (valproic acid and gabapentin). Depressive 
symptom severity was evaluated by means of the Hamil-
ton Rating Scale for Depression (HRSD):17 the total score 
(mean ± SD) was 20 ± 6 (range: 17–32) at baseline (t0) and 
7 ± 4 (range: 4–13) after one month of treatment (t1). The 
doses of trazodone ranged between 75–300 mg/day.
All patients had no concomitant medical illness, as shown 
by a general check-up and by blood and urine tests which 
were within the normal range.
The study was approved by the Ethics Committee at Pisa 
University and an informed written consent was completed 
by all patients.
Platelet separation
Venous blood (25 mL) was collected from fasting 
subjects between 08.00 and 09.00 a.m, during the months 
of November–December and then mixed with 3 mL 
of anticoagulant: sodium citrate (2.2%) and citric acid 
(1.2%). A second sample was collected after a month of 
monotherapy with trazodone.
Platelets membranes were prepared according to a 
standardized protocol. Platelet-rich plasma (PRP) was 
obtained by low speed centrifugation (150 × g for 15 min at 
20°C). Platelets were precipitated from PRP by centrifugation 
at 1,500 × g for 15 min at 20°C and stored at −80°C until 
binding assay which was carried out within two weeks. 
On the day of assay, platelets were homogenized in 10 mL 
buffer 50 mM Tris-HCl, 5 mM EDTA, pH 7.7, containing 
protease inhibitors (20 µg/mL trypsin inhibitor: 200 µg/mL 
bacitracine, 160 µg/mL benzamidine), with an ultrathurrax 
homogenizer and centrifuged at 48,000 × g for 15 min at 4°C. 
The ensuing pellet was suspended again in 10 mL buffer 
50 mM Tris-HCl, 5 mM EDTA, pH 7.7 and centrifuged 
twice at 48,000 × g for 15 min at 4°C. The ensuing pellet 
was suspended in an assay buffer (50 mM Tris-HCl).
[3H]-Rauwolscine binding assay
The [3H]-rauwolscine binding was carried out according 
to the methods of Corsano et al.18 Platelet membranes 
(0.2–0.5 mg proteins), suspended in an assay buffer, were 
incubated with 0.5 nM [3H]-rauwolscine (Sigma, Milan, 
Italy; specific activity: 71 Ci/mmol) for 60 min at 25°C in 
a final volume of 1 mL. The specific binding was evaluated 
with 10 mM cold clonidine (Sigma). To test the saturability 
of [3H]-rauwolscine specific binding sites, the platelet mem-
branes were incubated with eight increasing concentrations 
of [3H]-rauwolscine, ranging between 0.1 and 5 nM. After 
60 min, the incubation was halted by the addition of 5 mL Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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of cold buffer. Samples were rapidly filtered under vacuum 
through glass fiber filters Whatman GF/C, washed four times 
with 5 mL cold buffer, and placed in vials with 4 mL of 
scintillation cocktail. Radioactivity was measured by means 
of a beta-counter (Packard 1600 TR).
[3H]-Par binding assay
The [3H]-Par binding was carried out according to the 
method of Marazziti et al.19 The incubation mixture con-
sisted of 100 µL of platelet membranes (50–100 µg protein/
tube), 50 µL of [3H]-Par (Perkin-Elmer Life Science, Milano, 
Italy; specific activity: 19.1 Ci/mmol) at six concentrations 
ranging between 0.01 and 1 nM and 1.85 mL of assay buffer 
(50 mM Tris HCl, 120 mM NaCl, 5 mM KCl, pH 7.4). 
Specific binding was obtained as the binding remaining in 
the presence of 10 µM fluoxetine (Sigma) as a displacer. All 
samples were assayed in duplicate and incubated at 22°C for 
1 hour. The incubation was halted by adding 5 mL of cold 
assay buffer. The contents of the tubes were immediately 
filtered under vacuum through glass fibre filters GF/C and 
washed 3 times with 5 mL of assay buffer. Filters were then 
placed in vials with 4 mL of scintillation cocktail (Ready 
Safe scintillation cocktail; Beckman Coulter, Carlsbad, 
CA, USA) and radioactivity was measured by means of a 
beta-counter (Packard LS 1600). Proteins were measured 
according to the method of Peterson.20
Statistical analyses
Equilibrium-saturation binding data, the maximum binding 
capacity (Bmax, fmol/mg protein) and the dissociation constant 
(Kd, nM) were analysed by means of iterative curve-fitting 
computer programmes EBDA (Biosoft, Cambridge, UK).
The difference between Bmax and Kd, at the two assessment 
times was measured by means of the Student’s t-test 
(two-tailed, paired). The effect of age and sex on biological 
parameters was evaluated by means of the covariance analysis 
(ANCOVA). The possible correlations between biological 
findings and psychopathological data were analyzed according 
to the Pearson’s method. All analyses were carried out using 
SPSS; version 12.1; (SPSS Inc, Chicago, IL, USA).
Results
No significant effects of age, sex or diagnosis on [3H]-Par or 
[3H]-rauwolscine binding were observed.
As far as the [3H]-Par  binding  is  concerned, 
the Bmax values (mean ± SD, fmol/mg protein) showed a 
statistically-significant decrease at t1, as compared with t0 
(733 ± 30 vs 1471 ± 99, P , 0.001), while the Kd values 
(mean ± SD, nM) did not change at the two assessment 
times (Table 1).
Similarly, no difference was detected in Bmax or Kd values 
of [3H]-rauwolscine binding of the depressed patients before 
and after one month of treatment with trazodone.
No correlation between biological parameters and HRSD 
total score or single items was observed. No difference 
between unipolar and bipolar patients, or drug-free or 
previously-treated patients was detected.
Discussion
The present study, exploring the possible effects of one-
month’s treatment with trazodone on platelet SERT, as 
assessed by the [3H]-Par binding, and α2-adrenoceptors, 
measured by means of the [3H]-rauwolscine binding, of 
depressed patients, led to different findings. First, the bind-
ing parameters, Bmax and Kd, of [3H]-rauwolscine, a selective 
α2-antagonist, were not modified by the treatment with tra-
zodone. This is consistent with the pharmacological properties 
of trazodone: in fact, in vitro this compound does not provoke 
any effect on α2-adrenoceptors, while it interacts with α1- and 
5-HT2 receptors21 and shows a certain inhibitory activity on 
5-HT reuptake.22,23 This is confirmed by our observations of 
a significant decrease (about 50%) of the Bmax of [3H]-Par 
binding after one month of treatment. The change of Bmax with 
no modification of the Kd, which is the inverse of the affinity 
constant, suggests that trazodone provokes a decrease in the 
number of the SERT proteins, without affecting its affinity 
characteristics. Previously, it has been shown by different 
authors that SSRIs or tricyclics may modify [3H]-Par binding 
parameters in vivo, although data are quite controversial.24–28 
In particular, the Bmax of [3H]-Par binding, at t0 was similar in 
27 depressed patients and control subjects, albeit significantly 
lower in those patients at the first episode, and decreased after 
three months of treatment with fluoxetine or clomipramine.27 
The same result was obtained in a sample of 24 depressed 
children and adolescents after six weeks and also after 
Table  1 [ 3H]-Par  and  [3H]-Rauwolscine  bindings  parameters 
(Bmax, fmol/mg protein and Kd, nM, mean ± SD) in platelets of 
depressed patients
Bmax (fmol/mg prot) Kd (nM)
[3H]-Par (N = 25)
t0 1471 ± 99 0.11 ± 0.4
t1 733 ± 30* 0.1 ± 0.2
[3H]-Rauwolscine (N = 21)
t0 168 ± 33 0.78 ± 0.2
t1 169 ± 20 1.02 ± 0.4
Note: *significant, P , 0.001.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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six months of sertraline.26 On the contrary, sertraline given 
for six months to a small sample (n = 10) of adult depressed 
patients seemed to provoke an increased Bmax of [3H]-Par bind-
ing, while paroxetine led to the opposite findings in another 10 
patients.28 Although generally no change of the Kd has been 
detected, in one study this parameter was reported to increase 
after six weeks of treatment with fluoxetine or lofepramine 
in, respectively, 22 and 18 depressed patients,24 or to decrease 
in 45 depressed patients following SSRIS or tricyclics for at 
least one month.29 Therefore, in spite of these controversies 
regarding which parameter is modified by which drug, it seems 
that, in any case, the interference with the platelet SERT is 
essential for the development of the antidepressant effect.7 
Along this line, it is interesting to highlight that all patients 
enrolled in our study showed a significant decrease of the 
Bmax of [3H]-Par binding, in parallel with the improvement of 
depressive symptomatology, as revealed by the decrease of the 
HRSD total score. A significant correlation between changes 
in [3H]-Par Bmax and change in HRSD total score after four 
and eight weeks of treatment with paroxetine or fluoxetine 
was measured in a previous study in 21 depressed patients.25 
On the contrary, we could not detect this, perhaps because of 
the small sample size. For the same reason, maybe, we did 
not find any difference between unipolar or bipolar patients, 
or patients who were drug-free or had been treated one month 
previously, or were currently taking mood stabilizers: these 
last drugs, however, do not seem to interfere with [3H]-Par 
binding.19
In conclusion, our study shows that trazodone modifies 
the number of the SERT proteins in platelet membranes 
and suggests that these changes may underlie its short-term 
antidepressant properties and, perhaps, might be used as a 
predictor of response. Further studies should clarify whether 
this is the case also of long-term treatments.
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